UMC
Welcome,         Profile    Billing    Logout  
 1 Trial 
1 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eskens, Ferry ALM
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28

Download Options